What's going on with Race Oncology at the moment ?, page-21

This is specifically what was said in the May 2021 investor briefing.

So there's a question here, obviously the one on everybody lips - so when are we looking to have a discussion with big pharma can you just talk your timing around that please Phil.​

​

Yeah sure yeah it's a question we hear very often I think people are excited about what that means.​

My answer is simply that the better our data and the more data we have that will guide the quality of a discussion with Pharmas so we will start a a program we'll start it likely later in this year.​

​

But that campaign if I may call it that to market our company should be concentrated should be focused and should be deliberate and so when we started it will be exactly that a little bit like selling your house you don't want to sell your house over 12 months you need to do it on a concentrated basis and we'll do so later in the year.​

Go to around 38:54 in this video.



Brings me back to this timeline I put together for the Synthorx transaction ... under 6 months between patent dosing and the buyout offer.




1. https://www.sanofi.com/en/media-room/press-releases/2019/2019-12-09-07-00-00
2. https://www.fiercepharma.com/pharma/sanofi-beat-out-three-suitors-its-pricey-2-5b-buyout-biotech-synthorx
3. https://www.jefferies.com/CMSFiles/Jefferies.com/files/Synthorx%20v2.pdf
4. https://www.fiercebiotech.com/biotech/aacr-sanofi-s-engineered-il-2-clears-safety-hurdles-early-phase-1-data



Note - their drug I think has peak sales potential USD $0.5B to $1.0B based on looking at peer drugs for their drug, but the USD $2.5B buyout implies USD $0.5B peak sales. Based on metrics I've captured buyouts are typically around 5x peak sales. For context my view is that Bisantrene could achieve peak sales around USD $44B (immense value underpinning Bisantrene however I think breaching a USD $5B to USD $21B buyout window is unlikely ).